( effects inboth study arms. In additio...)Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint,Health

effects in both study arms. In addition, there was no statistically significant difference in the primary endpoint between patients receiving nesiritide compared to patients receiving placebo infusions when each was added to optimal heart failure medications, significant use of indicated heart failure devices and intensive disease management.

"The safety findings from the FUSION II trial and other recent clinical studies should be reassuring for physicians who use nesiritide to treat patients according to its currently labeled indication and who are evaluating the drug in ongoing investigations," said Clyde W. Yancy, M.D., Principal Investigator of FUSION II and Medical Director of the Baylor Heart and Vascular Institute at Medical Center at Dallas. "The relatively low clinical event rates observed in both treatment groups are consistent with previous investigations that have demonstrated the utility of rigorous disease management employing optimal medical and device therapies in the improvement of patient outcomes. This is an important message for practitioners."

In multiple rigorously-controlled clinical trials published in peer- reviewed medical journals, NATRECOR(R) was shown to significantly reduce pulmonary capillary wedge pressure and improve patient-reported dyspnea, an important symptom to relieve in patients with exacerbations of heart failure. Since NATRECOR(R) was approved by the FDA in August 2001, more than 800,000 ADHF patients in the United States have been treated with the drug.

FUSION II Study Design and Results

As a follow-up to the FUSION I study, which showed promising initial results in the advanced CDHF patient population, in March 2004 investigators began the prospective, randomized, placebo-controlled, double-blind, multicenter FUSION II trial to further assess the long-term outcomes in this patient group. The study enrolled 920 patients with advanced CDHF at more than 150 sites in the United States and abroad an
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product